Figs earnings ahead: Investors eye margins, customer growth

Figs is expected to report Q1 EPS of $0.01 on revenue of $152.48 million, up 22.08% year over year but well below last quarter's $201.90 million. Analysts remain constructive overall, with nine covering the stock at a consensus Buy and a mean target of $17.75 versus a $14.50 share price, though Morgan Stanley stays at Hold with a $15 target. Investors will focus on active customer growth, international momentum, and EBITDA margin expansion amid a mixed discretionary spending backdrop.

Analysis

FIGS is in the classic post-burst normalization phase: the stock still trades like a premium growth compounder, but the next several quarters are likely to be judged on customer retention and repeat cadence rather than headline growth. The key second-order issue is that if active customer adds decelerate, the company’s high gross margin model can still look healthy while operating leverage stalls, which is exactly where multiple compression tends to begin.

The market seems to be underestimating how sensitive this setup is to guidance more than the quarter itself. At ~50x forward earnings, even a small miss on traffic or international contribution can cause a disproportionate de-rating because the stock is priced for durable mid-teens growth plus margin expansion. Conversely, if management can frame international as a meaningful offset to domestic demand softness, FIGS can re-rate quickly since the investor base is still willing to pay up for a clean DTC medical-brand narrative.

A contrarian angle is that the “mixed discretionary backdrop” may be less of a threat than a valuation anchor: healthcare apparel is a niche with recurring replacement behavior, and that can support better durability than the market is giving credit for. The real risk is not demand collapse, but a normalization from pandemic-era engagement levels toward a slower, more mature trajectory — which would leave consensus estimates too high for 2025-2026 margins and force downward revisions over the next 1-2 earnings cycles.

Second-order winners are likely adjacent branded apparel platforms with lower expectations and more room for operating leverage if FIGS disappoints. If FIGS reports cleanly but offers cautious commentary, the downside may spill into other premium consumer names where investors are paying for margin expansion that depends on sustained traffic growth.

Key Decisions for Investors

• Short-dated bearish options: buy FIGS weekly or 1-2 month put spreads into earnings if implied volatility is below the magnitude of a 10-15% post-print move; payoff is best if guidance disappoints on customer growth or international.
• If already long FIGS, trim into the print and retain only a core position until management proves that active customer growth is re-accelerating; risk/reward is poor when the multiple already prices in margin expansion.
• Pair trade: long a lower-multiple branded apparel name / short FIGS for 1-3 months if you want exposure to consumer resilience without paying for perfection; FIGS is the leg most exposed to estimate revision risk.
• Look to buy FIGS only on a post-earnings reset below the current multiple if management confirms EBITDA margin expansion visibility into 2026; that would offer a better entry with a cleaner risk/reward than chasing pre-print.
• For event-driven accounts, set a tactical trigger: if the stock gaps up on stable revenue but weak customer commentary, fade the move over 5-10 trading days as the market usually re-prices the growth duration assumption.